AMR Insights is grateful to its sponsors for enabling EADA 2021:
The NIH NIAID program, “Chemistry Center for Combatting Antibiotic Resistant Bacteria” (CC4CARB) is an innovative chemistry center focused on the synthesis and delivery of rationally designed, focused libraries for the scientific community to use in Gram-negative antibacterial drug discovery. The ultimate objective of CC4CARB is to create a large collection of chemical matter specifically targeting Gram-negative threats.
To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.
INCATE is a partnership between academic members, industry, and other supporting partners. It will help to bridge the gap between research and industry for treatments, diagnostics and interventions that reduce the prevalence and impact of Antimicrobial Resistance (AMR). INCATE will do this through the provision of advice, the building of a community supporting ventures’ development, and targeted funding of up to €250k. It is open for applications now. Apply at email@example.com
The Foundation for Neglected Disease Research (FNDR) aims to be an excellent “Non-profit Research Organization” that will offer candidate drugs for Diseases of the Developing World. Its mission is to conduct innovative research, discover, develop, manufacture, sell novel chemical/biological agents of synthetic or natural origin, undertake clinical trials, make available and provide innovative, distinctive products, scientific services, consultancy and education that contribute to save and improve lives of human, animal and/or plant with a focus on global health diseases.
SONIX MEDICAL DEVICES
Sonix Medical Devices, Inc., is a US-based medical devices company focused on developing non-invasive products and technologies that can prevent and treat infections with the goal of saving millions of lives globally. Sonix-A8 is an innovative antibacterial technology that prevents and treats bacterial infections and combats Antimicrobial Resistance (AMR) without the use of antibiotics. ‘Sonix-A8’ is a patented breakthrough technology that prevents and controls Surgical Site Infections (SSI’s) and Hospital Acquired Infections (HAI’s). This technology kills bacteria, including superbugs like MRSA, and is effective on and below the skin surface, where traditional treatments can’t reach. The technology platform completely destroys biofilms and combats AMR.
The first company to develop an innovative medical device that can be used safely by professionals and patients to prevent and treat infections by killing bacteria without having to use antibiotics and ending the Antimicrobial Resistance (AMR) cycle.
The Centre for Cellular and Molecular Platforms, or C-CAMP an initiative supported by Department of Biotechnology, Govt of India is an enabler or catalyst of cutting-edge research and innovation in the life sciences since 2009. C-CAMP is also a member of the Bangalore Life Science Cluster (BLiSC). We facilitate Bioscience Research and Entrepreneurship by providing Research, Development, Training and Services in state-of-the-art Technology Platforms. As a part C-CAMP’s mandate of promoting entrepreneurship and innovation, C-CAMP has created and fostered an entrepreneur-friendly culture in and around Academic/Research environment through its involvement in Seed Funding Schemes for Startups, Entrepreneur Mentorship program and Bio-Incubation facility. At C-CAMP, we have established State-Of-The-Art Platform Technologies which are essential requirements for success and leadership in the field of Life Sciences. C-CAMP allows Investigators to use Techniques as tools and not be limited by Technological barriers while pursuing challenging scientific questions.
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. The Company is developing novel antimicrobial drugs from its “in-house” XF platform and also from recently acquired Biotherapeutic products that harness beneficial components of the human microbiome. We have two exciting late stage clinical assets and a range of earlier research programmes. XF-73 nasal is our novel Phase 2b clinical asset for the prevention of post-surgical Staphylococcal infections which reported positive top-line data in Q1 2021. The Phase 2b trial achieved it’s primary endpoint with >99% nasal bacterial load reduction (p<0.0001) by the XF-73 nasal gel, with an excellent safety profile and no treatment related adverse events reported. Further information on the results of the trial can be found here. Our XF drug platform acts via an ultra-rapid action that kills targeted bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance. Destiny Pharma also recently acquired global rights to NTCD-M3 for the prevention of recurring Clostridioides difficile gut infections that is planned to start Phase 3 studies in 2022. Destiny Pharma is also collaborating with SporeGen Limited on a novel treatment for the prevention of COVID-19 and similar respiratory viral infections using a Bacillus based approach. This project is at the preclinical development stage as are several earlier XF projects. The Company will look to enter selected partnerships to develop its assets and also apply for non-dilutive sources of grant and governmental funding, as it has done in the past, to assist in the development of its portfolio.
A strategy to accelerate global efforts towards universal health coverage and health emergency response Our strategy seeks to harness the momentum around testing for COVID-19, exploiting emerging digital innovations, and building on our organization’s 20-year experience as a product development partnership focused on diagnosis of tuberculosis (TB), malaria and fever management, hepatitis C, and neglected tropical diseases (NTDs).
DAY ZERO DIAGNOSTICS
Day Zero Diagnostics is developing rapid, whole genome sequencing-based diagnostics to modernize infectious disease diagnosis and treatment. We are harnessing the power of the genome to build technologies that both precisely identify the species and provide the comprehensive antibiotic susceptibility / resistance profile of a bacterial infection within hours, rather than days, so that patients can be treated with the most effective antibiotic quickly. Faster treatment with the right antibiotic saves lives and reduces the cost and complications associated with extended episodes of care.
Madam Therapeutics is a technology platform company and develops novel anti-microbial agents which are fast acting, attack biofilms, and are less likely to give rise to resistance. With our novel AI approach we can mine our large portfolio for either small spectrum and broad spectrum inti-microbial peptides with a good safety profile. Madam Therapeutics follows a ‘One Health’ approach for development of its products developing distinct products for human and veterinary use.
ILSE is a life science technology accelerator, business incubator and a science-driven research institute that works in partnership with innovators, affiliated academic and biomedical institutions. ILSE has joined the CARB-X Global Accelerator Network as an accelerator to provide knowhow, diagnostics expertise, business strategy and other support to CARB-X’s growing portfolio of innovative antibacterial development projects.